RxDoctor Payments Data

Therese Bertrand

Family Medicine · Cypress, TXNPI 1942303508

Payments from drug & device makers

$4,954in general payments, 2019–2025

Across 265 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$847
  • Lilly USA, LLC$502
  • AstraZeneca$476
  • AbbVie$462
  • Boehringer Ingelheim$328
  • Pfizer$323
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,954100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,954 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$54,909
Medicare patients
215
Services billed
1,220

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$70,649
JardianceEmpagliflozin31$36,235
JanuviaSitagliptin Phosphate12$17,050
RybelsusSemaglutide13$11,952
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,729
EliquisApixaban16$9,308
ShingrixVaricella-Zoster Ge/As01b/Pf22$4,823
Levothyroxine Sodium184$2,492
Atorvastatin Calcium193$2,145
Valsartan32$1,579
Wixela InhubFluticasone Propion/Salmeterol11$1,398
Rosuvastatin Calcium108$1,394
Pregabalin14$1,285
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$1,046
SynthroidLevothyroxine Sodium23$1,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$847$82,60182 claims
Boehringer IngelheimJardiance$328$36,23531 claims
MerckJanuvia$13$17,05012 claims
GSKTrelegy Ellipta, Shingrix$130$14,55235 claims
PfizerEliquis$323$9,30816 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$28$2,492184 claims
AbbVieSynthroid$462$1,00823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →